Survodutide
Clinical TrialsSurvodutide
A dual GLP-1 and glucagon receptor agonist from Boehringer Ingelheim researched for obesity and NASH (non-alcoholic steatohepatitis / liver fat disease).
Dose
Varies in research protocols; commonly titrated up to 4.8 mg weekly
Route
SubQ injection
Cycle
Ongoing in long-term research studies (e.g., 68 weeks or more)
Storage
Lyophilized powder vial: store sealed at 2-8°C away from light; -20°C for long-term storage. Tolerates short room-temperature transit.
What is Survodutide?
Survodutide, also known as BI 456906, is a novel investigational peptide developed by Boehringer Ingelheim and Zealand Pharma. It functions as a dual agonist of both the glucagon-like peptide-1 (GLP-1) receptor and the glucagon receptor. This unique mechanism of action aims to leverage the benefits of both pathways: GLP-1 agonism primarily contributes to appetite suppression, improved glucose homeostasis, and delayed gastric emptying, while glucagon receptor agonism is hypothesized to enhance energy expenditure and liver fat metabolism. Research is actively exploring its potential in conditions such as obesity and non-alcoholic steatohepatitis (NASH).
Key Benefits
- Weight reduction
- Liver fat reduction (NASH research)
- Metabolic improvement
- Appetite suppression
Mechanism of Action
- Dual GLP-1 and glucagon agonism
- Glucagon receptor enhances fat burning
- GLP-1 reduces appetite
- Both pathways improve liver metabolism
Best For
- Weight management research
- Liver disease research
- Metabolic health
Body Systems
🐾 Griffin Says...
Molecular Information
Molecular weight
4865.5 g/mol
Length
40 amino acids
Type
Synthetic peptide, GLP-1 and glucagon receptor co-agonist
Amino acid sequence
His-Gly-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Leu-Ser-Lys-Gln-Met-Glu-Glu-Glu-Ala-Val-Arg-Leu-Phe-Ile-Glu-Trp-Leu-Lys-Asn-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser
A pegylated version of the native GLP-1 and glucagon sequence, modified for extended half-life.
Pharmacokinetics
Time to peak
8-12 hours
Half-life
168 h
Time to clear
Approximately 5-6 weeks after last dose for full elimination
Based on phase 1 and 2 clinical data observations.
Research Indications
Obesity and Overweight
Research indicates significant and sustained body weight reduction in individuals with obesity or overweight, often exceeding 15% to 20% of baseline body weight over prolonged periods (e.g., 68 weeks).
Appetite Regulation
Studies suggest a marked reduction in appetite and food intake, contributing to negative energy balance and subsequent weight loss.
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Obesity/Weight Management | Starting at 0.6 mg once weekly, titrated up to a maintenance dose of 2.4 mg or 4.8 mg once weekly over 8-16 weeks. | Once weekly | Subcutaneous injection |
| NASH Resolution and Fibrosis Improvement | Titrated up to 2.4 mg or 4.8 mg once weekly. | Once weekly | Subcutaneous injection |
| Metabolic Syndrome Improvement | Titrated up to a maintenance dose of 2.4 mg or 4.8 mg once weekly. | Once weekly | Subcutaneous injection |
| Long-term Efficacy and Safety | 4.8 mg once weekly (after titration). | Once weekly | Subcutaneous injection |
In research settings, dose titration is common to mitigate gastrointestinal side effects, starting with lower doses and gradually increasing over several weeks.
Peptide Interactions
- Monitor Combination
Insulin secretagogues (e.g., sulfonylureas)
Concurrent use may increase the risk of hypoglycemia. Dose adjustment of the sulfonylurea may be necessary.
- Monitor Combination
Insulin
Concurrent use may increase the risk of hypoglycemia. Dose adjustment of insulin may be necessary.
- Use Caution
Oral Medications (narrow therapeutic index)
Survodutide, like other GLP-1 receptor agonists, can delay gastric emptying, potentially affecting the absorption of orally administered medications, especially those requiring rapid absorption or with a narrow therapeutic index. Monitoring is advised.
- Avoid
Other GLP-1 Receptor Agonists
Concurrent use with other GLP-1 receptor agonists is generally not recommended due to additive pharmacodynamic effects and increased risk of side effects without clear additional benefit.
- Monitor Combination
Alcohol
Alcohol can lower blood sugar and may interact with the glucose-lowering effects of survodutide. Excessive alcohol intake can also exacerbate liver conditions.
How to Reconstitute
- 1Not applicable: Survodutide is typically supplied as a pre-filled pen or sterile solution, ready for administration.
What to Expect
- Weeks 1-4: Initiation of treatment may involve a titration phase with lower doses. Some individuals may start to experience mild gastrointestinal side effects such as nausea or diarrhea. Initial modest reductions in appetite may be observed.
- Weeks 4-12: As the dose is gradually increased, appetite suppression is commonly reported to become more pronounced. Early indicators of metabolic improvements, such as better glycemic control, might be noted. Weight loss, if a goal, typically becomes more consistent.
- Months 3-6: Significant weight reduction is often observed in research participants, alongside improvements in various metabolic markers. Liver fat reduction, particularly in NASH research, may begin to show early signs of efficacy in this timeframe.
- Months 6+: Continued weight management and sustained metabolic improvements are generally reported. Long-term studies investigate the sustained impact on liver health, cardiovascular markers, and overall body composition.
Side Effects & Safety
| Effect | Frequency | Severity |
|---|---|---|
| Nausea | Common | Mild |
| Vomiting | Uncommon | Mild |
Ready to calculate your dose? Use Griffin's Peptide Calculator 🐾
Open CalculatorPeptides discussed here are for research purposes only. Nothing on this page is medical advice. Always consult a qualified professional before making health decisions.